Search

Displaying results 2541 - 2550 of 6830 in total
  1. Drug

    Cinnamaldehyde

    go.drugbank.com/drugs/DB14184
    Approved

    Sensitivity to cinnamaldehyde may be identified with a clinical patch test.

  2. Drug

    Raloxifene

    go.drugbank.com/drugs/DB00481
    ApprovedInvestigational

    However, due to the off-target actions by HRT, newer non-hormonal agents such as raloxifene and [tamoxifen] have been developed to reduce adverse events through selective pharmacological actions on tissue-specific … Due to the risk of bone fractures that may lead to morbidities and reduced quality of life, the management of osteoporosis in postmenopausal women with the use of therapeutic agents in addition to concurrent

  3. Drug

    Dosulepin

    go.drugbank.com/drugs/DB09167
    ApprovedInvestigational

    It is not FDA-approved due to low therpeutic index and significant toxicity in overdose. … The use of dosulepsin is only recommended in patients who are intolerant or unresponsive to alternative antidepressant therapies.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    Lacidipine

    go.drugbank.com/drugs/DB09236
    Approved

    When visualized by small-angle X-ray diffraction with angstrom resolution to examine its location within the membranes, lacidipine was found deep within the membrane's hydrocarbon core [A31539]. … Due to its long duration of action, lacidipine does not lead to reflex tachycardia [A31536].

  5. Drug

    Butoconazole

    go.drugbank.com/drugs/DB00639
    Approved

    Butoconazole is an imidazole antifungal used in gynecology.

  6. Drug

    Latamoxef

    go.drugbank.com/drugs/DB04570
    Approved

    Latamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins

  7. Drug

    Centanafadine

    go.drugbank.com/drugs/DB14841
    ApprovedInvestigational

    [L63806] Its mechanism in ADHD is unclear, but its efficacy may be mediated by this triple reuptake inhibition, which increases the availability of all three neurotransmitters in pathways involved in attention

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    Lutetium Lu 177 dotatate

    go.drugbank.com/drugs/DB13985
    ApprovedInvestigational

    molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. … Lutetium Lu 177 dotatate was approved by the FDA as Lutathera in January 2018 for intravenous injection.

  9. Drug

    Mobocertinib

    go.drugbank.com/drugs/DB16390
    ApprovedInvestigationalWithdrawn

    1.5- to 10-fold lower than those required to inhibit wild-type EGFR. … as compared to "classical" _EGFR_ mutants causing NSCLC) and are associated with resistance to standard targeted EGFR inhibitors.

  10. Drug

    Maprotiline

    go.drugbank.com/drugs/DB00934
    Approved

    It differs from TCAs in that it does not appear to block serotonin reuptake. … Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs).

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome